Article: Management of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007-2008

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleManagement of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007-2008
AuthorsSamaranayake, NR1
Ong, KL2
Leung, RYH1
Cheung, BMY1
Issue Date2012
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/annepidem
CitationAnnals of Epidemiology, 2012, v. 22 n. 5, p. 349-353 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.annepidem.2012.01.001
AbstractPURPOSE: The prevalence of obesity has been increasing in the United States. We set out to investigate the use of pharmacologic and non-pharmacologic therapy for the treatment of obesity in recent years. METHODS: We included 2630 men and 2702 women who took part in the National Health and Nutrition Examination Survey from 2007 to 2008. We analyzed their demographic and anthropometric data and their weight and drug history. RESULTS: A total of 45.9% of men and 45.0% of women were candidates for treatment (body mass index >/=30 kg/m(2), or >/=27 kg/m(2) with risk factors). Among these participants, 85.1% considered themselves overweight, 90.1% would like to lose weight, 61.9% had dietary changes, 36.5% exercised, 3.7% took nonprescription drugs, and 2.2% took prescription drugs to control weight during the preceding year. During the preceding month, 0.5% and 0.1% of participants were taking phentermine and orlistat, respectively. There were no participants on sibutramine. CONCLUSIONS: Although obesity is highly prevalent, only a small percentage of obese Americans are on anti-obesity medication. The withdrawal of sibutramine would have minimal impact on the general population. There is a need for more lifestyle changes in the majority of obese individuals.
ISSN1047-2797
2011 Impact Factor: 3.215
2011 SCImago Journal Rankings: 0.244
DOIhttp://dx.doi.org/10.1016/j.annepidem.2012.01.001
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorSamaranayake, NR
dc.contributor.authorOng, KL
dc.contributor.authorLeung, RYH
dc.contributor.authorCheung, BMY
dc.date.accessioned2012-09-05T05:31:50Z
dc.date.available2012-09-05T05:31:50Z
dc.date.issued2012
dc.description.abstractPURPOSE: The prevalence of obesity has been increasing in the United States. We set out to investigate the use of pharmacologic and non-pharmacologic therapy for the treatment of obesity in recent years. METHODS: We included 2630 men and 2702 women who took part in the National Health and Nutrition Examination Survey from 2007 to 2008. We analyzed their demographic and anthropometric data and their weight and drug history. RESULTS: A total of 45.9% of men and 45.0% of women were candidates for treatment (body mass index >/=30 kg/m(2), or >/=27 kg/m(2) with risk factors). Among these participants, 85.1% considered themselves overweight, 90.1% would like to lose weight, 61.9% had dietary changes, 36.5% exercised, 3.7% took nonprescription drugs, and 2.2% took prescription drugs to control weight during the preceding year. During the preceding month, 0.5% and 0.1% of participants were taking phentermine and orlistat, respectively. There were no participants on sibutramine. CONCLUSIONS: Although obesity is highly prevalent, only a small percentage of obese Americans are on anti-obesity medication. The withdrawal of sibutramine would have minimal impact on the general population. There is a need for more lifestyle changes in the majority of obese individuals.
dc.description.naturepublished_or_final_version
dc.identifier.citationAnnals of Epidemiology, 2012, v. 22 n. 5, p. 349-353 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.annepidem.2012.01.001
dc.identifier.citeulike10318482
dc.identifier.doihttp://dx.doi.org/10.1016/j.annepidem.2012.01.001
dc.identifier.epage353
dc.identifier.hkuros204052
dc.identifier.issn1047-2797
2011 Impact Factor: 3.215
2011 SCImago Journal Rankings: 0.244
dc.identifier.issue5
dc.identifier.pmid22305325
dc.identifier.scopuseid_2-s2.0-84860246159
dc.identifier.spage349
dc.identifier.urihttp://hdl.handle.net/10722/163481
dc.identifier.volume22
dc.languageeng
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/annepidem
dc.publisher.placeUnited States
dc.relation.ispartofAnnals of Epidemiology
dc.relation.referencesReferences in Scopus
dc.rightsNOTICE: this is the author’s version of a work that was accepted for publication in Annals of Epidemiology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Annals of Epidemiology, 2012, v. 22 n. 5, p. 349-353. DOI: 10.1016/j.annepidem.2012.01.001
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
dc.subject.meshAnti-Obesity Agents - therapeutic use
dc.subject.meshCyclobutanes - therapeutic use
dc.subject.meshExercise
dc.subject.meshNutrition Surveys
dc.subject.meshObesity - epidemiology - therapy
dc.titleManagement of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007-2008
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong
  2. Heart Research Institute Australia